Luye Pharma Group Ltd. (HKG:2186)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Alimentary Tract and Metabolism Drugs	388.87M	450.42M	632.36M	898.46M	733.41M
Alimentary Tract and Metabolism Drugs Growth	-13.66%	-28.77%	-29.62%	22.50%	-26.99%
Oncology Drugs	2.08B	2.12B	2.31B	1.41B	2.24B
Oncology Drugs Growth	-1.78%	-7.96%	63.06%	-36.73%	-20.50%
Others	314.67M	188.30M	185.02M	136.61M	165.09M
Others Growth	67.12%	1.77%	35.44%	-17.25%	3.57%
Cardio-Vascular System Drugs	1.66B	1.69B	1.54B	1.43B	1.00B
Cardio-Vascular System Drugs Growth	-1.62%	9.87%	7.60%	42.09%	-3.71%
Central Nervous System Drugs	1.61B	1.69B	1.32B	1.32B	1.40B
Central Nervous System Drugs Growth	-4.80%	28.12%	-0.08%	-5.55%	4.66%
Total	6.06B	6.14B	5.98B	5.20B	5.54B
Total Growth	-1.33%	2.70%	15.03%	-6.13%	-12.87%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Mainland China	4.92B	5.03B	5.03B	4.24B	4.51B
Mainland China Growth	-2.09%	-0.03%	18.73%	-6.07%	-15.21%
Other Countries	202.67M	216.77M	298.85M	274.78M	280.21M
Other Countries Growth	-6.51%	-27.46%	8.76%	-1.94%	-22.94%
Asia (Other than Chinese Mainland)	347.49M	446.73M	342.47M	443.85M	505.20M
Asia (Other than Chinese Mainland) Growth	-22.21%	30.44%	-22.84%	-12.14%	27.36%
European Union	586.67M	449.98M	309.17M	244.08M	242.79M
European Union Growth	30.38%	45.54%	26.67%	0.53%	-12.24%
Total	6.06B	6.14B	5.98B	5.20B	5.54B
Total Growth	-1.33%	2.70%	15.03%	-6.13%	-12.87%

Source: S&P Global Market Intelligence.